for people ages 18 years and up (full criteria)
at UC Davis
study started
completion around
Principal Investigator
by Mehrdad Abedi, MD (ucdavis)



Mucosal-dominant pemphigus vulgaris (mPV) is a B-cell mediated autoimmune disorder in which painful blisters are formed on the mucosal membrane, including the mouth, nose, throat, eyelids, anus, and genitals. This phase 1 study is being conducted to find the maximum tolerated dose and optimal fractionated infusion schedule of an investigational cell therapy, DSG3-CAART, that can be given to patients with mPV who are inadequately managed by standard therapies. DSG3-CAART may potentially lead to complete and durable remission of disease.

Official Title

A Phase 1, Open-label, Safety and Dosing Study of Autologous Desmoglein 3 Chimeric Autoantibody Receptor T Cells (DSG3-CAART) in Subjects With Active, Anti-DSG3, Mucosal-dominant Pemphigus Vulgaris


Mucosal -Dominant Pemphigus Vulgaris, Pemphigus, Pemphigus Vulgaris, CAAR-T Therapy, CAR-T Therapy, Desmoglein 3, Cell Therapy, Autoimmune Disease, Autoimmunity, Skin Diseases, Vesiculobullous, Immunotherapy, Adoptive, Immune System Diseases, DSG3-CAART


You can join if…

Open to people ages 18 years and up

  • Confirmed diagnosis of mPV by prior or screening biopsy and prior positive anti- DSG3 antibody ELISA
  • mPV inadequately managed by at least one standard immunosuppressive therapies
  • Active mPV at screening
  • Anti-DSG3 antibody ELISA positive at screening

You CAN'T join if...

  • Active cutaneous lesions associated with PV that indicates mucocutaneous rather than mucosal-dominant disease
  • Rituximab in last 12 months unless PV symptoms have recently worsened or anti-DSG3 antibody titers have recently increased
  • Prednisone > 0.25mg/kg/day
  • Other autoimmune disorder requiring immunosuppressive therapies
  • Investigational treatment in last 6 months
  • Absolute lymphocyte count < 1,000/µL at screening


  • UC Davis, Dept. of Dermatology accepting new patients
    Sacramento California 95816 United States
  • Stanford University, Dept. of Dermatology accepting new patients
    Redwood City California 94063 United States

Lead Scientist at University of California Health

  • Mehrdad Abedi, MD (ucdavis)
    Professor, Hematology and Oncology, School of Medicine. Authored (or co-authored) 69 research publications


accepting new patients
Start Date
Completion Date
Cabaletta Bio
Phase 1 research study
Study Type
Expecting 39 study participants
Last Updated